Hiten D. Patel, MD, MPH

Hiten D. Patel, MD, MPH, completed residency training in urologic surgery at the James Buchanan Brady Urological Institute and is currently a clinical instructor and fellow in urologic oncology at Loyola University Medical Center. He has published studies related to epidemiology, comparative effectiveness, evidence-based reviews, and clinical trials in urologic oncology and related fields.

Articles by Hiten D. Patel, MD, MPH

Hiten D. Patel, MD, MPHJournal | December 14, 2021
Dr. Michael S Hofman reported findings from the phase 2 TheraP (ANZUP 1603) clinical trial.
Read More
Hiten D. Patel, MD, MPHJournal | December 14, 2021
Dr. Sumanta K. Pal et al, reported the results of the study comparing three MET inhibitors with sunitinib in pRCC.
Hiten D. Patel, MD, MPHJournal | December 14, 2021
These results formed the basis for the FDA’s approval of enzalutamide for the treatment of patients with mHSPC.
Hiten D. Patel, MD, MPHASCO GU Symposium 2021 | March 26, 2021
Efortumab vedotin prolonged OS in patients who had previously received chemotherapy and checkpoint inhibitors.
Hiten D. Patel, MD, MPHASCO GU Symposium 2021 | March 10, 2023
The phase 3 CLEAR trial showed improved OS for lenvatinib plus pembrolizumab as first-line therapy for advanced RCC.
Hiten D. Patel, MD, MPHASCO GU Symposium 2021 | March 26, 2021
Nivolumab improves disease-free survival, non-urothelial tract recurrence-free survival, and metastasis-free survival.
Hiten D. Patel, MD, MPHASCO GU Symposium 2021 | August 23, 2023
The phase 2 SWOG 1500 trial showed improvement in progression-free survival for cabozantinib in metastatic papillary RCC.
Hiten D. Patel, MD, MPHASCO GU Symposium 2021 | May 7, 2023
Relugolix represents a new oral option for GnRH receptor antagonism.
Hiten D. Patel, MD, MPHASCO GU Symposium 2021 | December 2, 2022
Establishing Cabazitaxel as third-line therapy for metastatic castration-resistant prostate cancer by the phase 4 CARD trial.
Hiten D. Patel, MD, MPHASCO GU Symposium 2021 | February 22, 2021
177Lu-PSMA-617 was able to generate more PSA responses of at least 50% reduction compared to taxane cabazitaxel in mCRPC.
Hiten D. Patel, MD, MPHASCO GU Symposium 2021 | October 12, 2023
Adding enzalutamide to androgen deprivation therapy improved progression-free survival in hormone-sensitive prostate cancer.